Advances in nanomaterials for the diagnosis and treatment of ischemic heart disease
Source abstract
Abstract
Abstract Ischemic heart disease (IHD) remains a leading cause of mortality worldwide. Despite timely reperfusion therapy, myocardial ischemia can still lead to ventricular remodeling, arrhythmia, and heart failure, contributing to the high prevalence of cardiovascular disease. Nanomaterials provides innovative technical methods and tools for precise clinical diagnosis and effective treatment through nanoscale control of materials and biological interactions. In this study, bibliometrics have been harnessed to explore the region and topic distribution characteristics of nanotechnology in the field of ischemic cardiomyopathy. The key directions in this field contain cardiac tissue engineering, biosensor, targeted drug delivery and molecular imaging. China and USA are the leading contributors in this filed. Recent literature demonstrates rapid growth in nanomaterial-based strategies and their broad application in preclinical models of IHD. However, only a limited number of nanomedicine products have progressed to clinical approval. This review summarizes the current advances in nanotechnology for IHD, highlights remaining challenges, and discusses future directions to facilitate clinical translation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Cardiac Ischemia and Reperfusion · Cardiac Fibrosis and Remodeling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237–69. https://doi.org/10.1093/eurheartj/ehy462.10.1093/eurheartj/ehy462 ↗
2. Cardiovascular diseases (CVDs). https://www.who.int. Accessed June 12, 2024.
3. Zheng Z, Zhu S, Lv M, Gu Z, Hu H. Harnessing nanotechnology for cardiovascular disease applications - a comprehensive review based on bibliometric analysis. Nano Today. 2022;44:101453. https://doi.org/10.1016/j.nantod.2022.101453.10.1016/j.nantod.2022.101453 ↗
4. Archambault E, Campbell D, Gingras Y, Lariviere V. Comparing of science bibliometric statistics obtained from the web and scopus. J Am Soc Inf Sci Technol. 2009;60:1320–6. https://doi.org/10.1002/asi.21062.10.1002/asi.21062 ↗
5. Li D, Son Y, Jang M, Wang S, Zhu W. Nanoparticle based cardiac specific drug delivery. Biology. 2023;12:82. https://doi.org/10.3390/biology12010082.10.3390/biology12010082 ↗
6. Lim B-K, Tighe EC, Kong SD. The use of magnetic targeting for drug delivery into cardiac myocytes. J Magn Magn Mater. 2019;473:21–5. https://doi.org/10.1016/j.jmmm.2018.09.118.10.1016/j.jmmm.2018.09.118 ↗
7. Millart E, Lesieur S, Faivre V. Superparamagnetic lipid-based hybrid nanosystems for drug delivery. Expert Opin Drug Deliv. 2018;15:523–40. https://doi.org/10.1080/17425247.2018.1453804.10.1080/17425247.2018.1453804 ↗
8. Gao M, Tang M, Ho W, et al. Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis. ACS Nano. 2023;17:17721–39. https://doi.org/10.1021/acsnano.3c00958.10.1021/acsnano.3c00958 ↗
9. Fu X, Yu X, Jiang J, et al. Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis. Nat Commun. 2022;13:6528. https://doi.org/10.1038/s41467-022-34248-y.10.1038/s41467-022-34248-y ↗
10. Wang S, Zhang J, Li W, et al. Hyaluronic acid-guided assembly of ceria nanozymes as plaque-targeting ROS scavengers for anti-atherosclerotic therapy. Carbohydr Polym. 2022;296:119940. https://doi.org/10.1016/j.carbpol.2022.119940.10.1016/j.carbpol.2022.119940 ↗
11. Gong F, Wang Z, Mo R, et al. Nano-sponge-like liposomes remove cholesterol crystals for antiatherosclerosis. J Control Release: Off J Control Release Soc. 2022;349:940–53. https://doi.org/10.1016/j.jconrel.2022.07.021.10.1016/j.jconrel.2022.07.021 ↗
12. Kim H, Han J, Park J-H. Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity. J Control Release: Off J Control Release Soc. 2020;319:77–86. https://doi.org/10.1016/j.jconrel.2019.12.021.10.1016/j.jconrel.2019.12.021 ↗
13. Jin H, Lu W, Zhang Y, et al. Functionalized periodic mesoporous silica nanoparticles for inhibiting the progression of atherosclerosis by targeting low-density lipoprotein cholesterol. Pharmaceutics. 2024;16:74. https://doi.org/10.3390/pharmaceutics16010074.10.3390/pharmaceutics16010074 ↗
14. Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. Ebiomedicine. 2021;74:103725. https://doi.org/10.1016/j.ebiom.2021.103725.10.1016/j.ebiom.2021.103725 ↗
15. Tu S, Ren W, Han J, et al. Polydopamine nanoparticle-mediated mild photothermal therapy for inhibiting atherosclerotic plaque progression by regulating lipid metabolism of foam cells. Regener Biomater. 2023;10:rbad031. https://doi.org/10.1093/rb/rbad031.10.1093/rb/rbad031 ↗
16. Zhang R, Luo S, Hao L-K, et al. Preparation and properties of Thrombus-Targeted Urokinase/Multi-Walled carbon nanotubes (MWCNTs)-Chitosan (CS)-RGD drug delivery system. J Biomed Nanotechnol. 2021;17:1711–25. https://doi.org/10.1166/jbn.2021.3113.10.1166/jbn.2021.3113 ↗
17. Guo X, Hong T, Zang J, et al. Thrombus-specific/responsive biomimetic nanomedicine for Spatiotemporal thrombolysis and alleviation of myocardial ischemia/reperfusion injury. J Nanobiotechnol. 2022;20:531. https://doi.org/10.1186/s12951-022-01686-1.10.1186/s12951-022-01686-1 ↗
18. Yu H, Li Y, Zhang R, et al. Inhibition of cardiomyocyte apoptosis post-acute myocardial infarction through the efficient delivery of microRNA-24 by silica nanoparticles. Nanoscale Adv. 2021;3:6379–85. https://doi.org/10.1039/d1na00568e.10.1039/d1na00568e ↗
19. Fan C, Oduk Y, Zhao M, et al. Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1. Jci Insight. 2020;5:e132796. https://doi.org/10.1172/jci.insight.132796.10.1172/jci.insight.132796 ↗
20. Somasuntharam I, Yehl K, Carroll SL, et al. Knockdown of TNF-α by DNAzyme gold nanoparticles as an anti-inflammatory therapy for myocardial infarction. Biomaterials. 2016;83:12–22. https://doi.org/10.1016/j.biomaterials.2015.12.022.10.1016/j.biomaterials.2015.12.022 ↗
21. Li T, Feng J, Ding W, Zhang Z. Targeted treatment of myocardial infarction by macrophage membrane coated with Resveratrol nanoparticles. ACS Omega. 2024;9:47145–55. https://doi.org/10.1021/acsomega.4c07573.10.1021/acsomega.4c07573 ↗
22. Hu D, Li R, Li Y, et al. Inflammation-targeted nanomedicines alleviate oxidative stress and reprogram macrophages polarization for myocardial infarction treatment. Adv Sci (Weinh Baden-Wurtt Ger). 2024;11:e2308910. https://doi.org/10.1002/advs.202308910.10.1002/advs.202308910 ↗
23. Wang L, Peng Y, Song L, et al. Colchicine-containing nanoparticles attenuates acute myocardial infarction injury by inhibiting inflammation. Cardiovasc Drugs Ther. 2022;36:1075–89. https://doi.org/10.1007/s10557-021-07239-2.10.1007/s10557-021-07239-2 ↗
24. Sun L, Hu Y, Mishra A, et al. Protective role of poly(lactic-co‐glycolic) acid nanoparticle loaded with Resveratrol against isoproterenol‐induced myocardial infarction. BioFactors. 2020;46:421–31. https://doi.org/10.1002/biof.1611.10.1002/biof.1611 ↗
25. Su T, Huang K, Ma H, et al. Platelet-inspired nanocells for targeted heart repair after ischemia/reperfusion injury. Adv Funct Mater. 2019;29:1803567. https://doi.org/10.1002/adfm.201803567.10.1002/adfm.201803567 ↗
26. Wang Q, Song Y, Gao J, et al. Hippo pathway-manipulating neutrophil-mimic hybrid nanoparticles for cardiac ischemic injury via modulation of local immunity and cardiac regeneration. Acta Pharm Sin B. 2023;13:4999–5015. https://doi.org/10.1016/j.apsb.2023.08.021.10.1016/j.apsb.2023.08.021 ↗
27. Wang B, Wu C, He S, et al. V1-cal hydrogelation enhances its effects on ventricular remodeling reduction and cardiac function improvement post myocardial infarction. Chem Eng J (Lausanne Switz: 1996). 2022;433:134450. https://doi.org/10.1016/j.cej.2021.134450.10.1016/j.cej.2021.134450 ↗
28. Varshosaz J, Masoudi S, Mehdikhani M, Beni BH, Farsaei S. Atorvastatin lipid nanocapsules and gold nanoparticles embedded in injectable thermo-gelling hydrogel scaffold containing adipose tissue extracellular matrix for myocardial tissue regeneration. IET Nanobiotechnol. 2019;13:933–41. https://doi.org/10.1049/iet-nbt.2019.0035.10.1049/iet-nbt.2019.0035 ↗
29. Yu D, Wang X, Ye L. Cardiac tissue engineering for the treatment of myocardial infarction. JCDD. 2021;8:153. https://doi.org/10.3390/jcdd8110153.10.3390/jcdd8110153 ↗
30. Milan PB, Amini N, Mehrabi A, Mousazadeh S, Ababzadeh S, Rezapour A. Cell sources in cardiac tissue engineering: current choices. CSCR. 2021;16:745–52. https://doi.org/10.2174/1574888X16666210120101223.10.2174/1574888X16666210120101223 ↗
31. Moghadasi S, Elveny M, Rahman HS, et al. A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine. J Transl Med. 2021;19:302. https://doi.org/10.1186/s12967-021-02980-6.10.1186/s12967-021-02980-6 ↗
32. Amin R, Sink D, Narayan E, Abdel-Hafiz SP, Mestroni M, Peña L. Nanomaterials for cardiac tissue engineering. Molecules. 2020;25:5189. https://doi.org/10.3390/molecules25215189.10.3390/molecules25215189 ↗
33. Cleutjens JPM, Creemers E. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J Card Fail. 2002;8:S344–8. https://doi.org/10.1054/jcaf.2002.129261.10.1054/jcaf.2002.129261 ↗
34. Roacho-Pérez JA, Garza-Treviño EN, Moncada-Saucedo NK, et al. Artificial scaffolds in cardiac tissue engineering. Life. 2022;12:1117. https://doi.org/10.3390/life12081117.10.3390/life12081117 ↗
35. Keshvardoostchokami M, Majidi SS, Huo P, Ramachandran R, Chen M, Liu B. Electrospun nanofibers of natural and synthetic polymers as artificial extracellular matrix for tissue engineering. Nanomaterials. 2020;11:21. https://doi.org/10.3390/nano11010021.10.3390/nano11010021 ↗
36. Chen J, Zhan Y, Wang Y, et al. Chitosan/silk fibroin modified nanofibrous patches with mesenchymal stem cells prevent heart remodeling post-myocardial infarction in rats. Acta Biomater. 2018;80:154–68. https://doi.org/10.1016/j.actbio.2018.09.013.10.1016/j.actbio.2018.09.013 ↗
37. Sridhar S, Venugopal JR, Sridhar R, Ramakrishna S. Cardiogenic differentiation of mesenchymal stem cells with gold nanoparticle loaded functionalized nanofibers. Colloids Surf B. 2015;134:346–54. https://doi.org/10.1016/j.colsurfb.2015.07.019.10.1016/j.colsurfb.2015.07.019 ↗
38. Liu Q, Tian S, Zhao C, et al. Porous nanofibrous poly(L-lactic acid) scaffolds supporting cardiovascular progenitor cells for cardiac tissue engineering. Acta Biomater. 2015;26:105–14. https://doi.org/10.1016/j.actbio.2015.08.017.10.1016/j.actbio.2015.08.017 ↗
39. Ghovvati M, Kharaziha M, Ardehali R, Annabi N. Recent advances in designing electroconductive biomaterials for cardiac tissue engineering. Adv Healthc Mater. 2022;11:2200055. https://doi.org/10.1002/adhm.202200055.10.1002/adhm.202200055 ↗
40. Nair RS, Sobhan PK, Shenoy SJ, et al. A Porcine cholecystic extracellular matrix conductive scaffold for cardiac tissue repair. J Biomed Mater Res. 2022;110:2039–49. https://doi.org/10.1002/jbm.b.35058.10.1002/jbm.b.35058 ↗
41. Ul Haq A, Carotenuto F, Trovalusci F, De Matteis F, Di Nardo P. Carbon Nanomaterials-Based electrically conductive scaffolds to repair the ischaemic heart tissue. C. 2022;8:72. https://doi.org/10.3390/c8040072.10.3390/c8040072 ↗
42. Shokraei N, Asadpour S, Shokraei S, Sabet MN, Faridi-Majidi R, Ghanbari H. Development of electrically conductive hybrid nanofibers based on CNT-polyurethane nanocomposite for cardiac tissue engineering. Microsc Res Tech. 2019;82:1316–25. https://doi.org/10.1002/jemt.23282.10.1002/jemt.23282 ↗
43. Mousa HM, Ali MG, Rezk AI, Nasr EA, Hussein KH. Development of conductive polymeric nanofiber patches for cardiac tissue engineering application. J Appl Polym Sci. 2022;139. https://doi.org/10.1002/app.52757.10.1002/app.52757 ↗
44. Zhu K, Guo C, Lai H, et al. Novel hyperbranched polyamidoamine nanoparticles for transfecting skeletal myoblasts with vascular endothelial growth factor gene for cardiac repair. J Mater Sci-Mater Med. 2011;22:2477–85. https://doi.org/10.1007/s10856-011-4424-2.10.1007/s10856-011-4424-2 ↗
45. Hu T, Wu Y, Zhao X, et al. Micropatterned, electroactive, and biodegradable poly(glycerol sebacate)-aniline trimer elastomer for cardiac tissue engineering. Chem Eng J. 2019;366:208–22. https://doi.org/10.1016/j.cej.2019.02.072.10.1016/j.cej.2019.02.072 ↗
46. López-Canosa A, Perez-Amodio S, Yanac-Huertas E, et al. A microphysiological system combining electrospun fibers and electrical stimulation for the maturation of highly anisotropic cardiac tissue. Biofabrication. 2021;13:035047. https://doi.org/10.1088/1758-5090/abff12.10.1088/1758-5090/abff12 ↗
47. Elkhoury K, Morsink M, Sanchez-Gonzalez L, Kahn C, Tamayol A, Arab-Tehrany E. Biofabrication of natural hydrogels for cardiac, neural, and bone tissue engineering applications. Bioactive Mater. 2021;6:3904–23. https://doi.org/10.1016/j.bioactmat.2021.03.040.10.1016/j.bioactmat.2021.03.040 ↗
48. Tijore A, Irvine SA, Sarig U, Mhaisalkar P, Baisane V, Venkatraman S. Contact guidance for cardiac tissue engineering using 3D bioprinted gelatin patterned hydrogel. Biofabrication. 2018;10:025003. https://doi.org/10.1088/1758-5090/aaa15d.10.1088/1758-5090/aaa15d ↗
49. Wu Y, Wang L, Guo B, Ma PX. Interwoven aligned conductive nanofiber Yarn/Hydrogel composite scaffolds for engineered 3D cardiac anisotropy. ACS Nano. 2017;11:5646–59. https://doi.org/10.1021/acsnano.7b01062.10.1021/acsnano.7b01062 ↗
50. Joddar B, Natividad-Diaz SL, Padilla AE, et al. Engineering approaches for cardiac organoid formation and their characterization. Translational Res. 2022;250:46–67. https://doi.org/10.1016/j.trsl.2022.08.009.10.1016/j.trsl.2022.08.009 ↗
51. Zhang YS, Arneri A, Bersini S, et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials. 2016;110:45–59. https://doi.org/10.1016/j.biomaterials.2016.09.003.10.1016/j.biomaterials.2016.09.003 ↗
52. Li Q, Nan K, Le Floch P, et al. Cyborg organoids: implantation of nanoelectronics via organogenesis for Tissue-Wide electrophysiology. Nano Lett. 2019;19:5781–9. https://doi.org/10.1021/acs.nanolett.9b02512.10.1021/acs.nanolett.9b02512 ↗
53. Zheng Z, Zhu S, Wang X, et al. Understanding the mechanism of cardiotoxicity induced by nanomaterials: a comprehensive review. Small Sci. 2025;5:2400498. https://doi.org/10.1002/smsc.202400498.10.1002/smsc.202400498 ↗
54. Abdelwahid E, Kalvelyte A, Stulpinas A, de Carvalho KAT, Guarita-Souza LC, Foldes G. Stem cell death and survival in heart regeneration and repair. Apoptosis. Int J Program Cell Death. 2016;21:252–68. https://doi.org/10.1007/s10495-015-1203-4.10.1007/s10495-015-1203-4 ↗
55. Mani V, Durmus C, Khushaim W, et al. Multiplexed sensing techniques for cardiovascular disease biomarkers - A review. Biosens Bioelectron. 2022;216:114680. https://doi.org/10.1016/j.bios.2022.114680.10.1016/j.bios.2022.114680 ↗
56. Szunerits S, Mishyn V, Grabowska I, Boukherroub R. Electrochemical cardiovascular platforms: current state of the Art and beyond. Biosens Bioelectron. 2019;131:287–98. https://doi.org/10.1016/j.bios.2019.02.010.10.1016/j.bios.2019.02.010 ↗
57. Liu R, Ye X, Cui T. Recent progress of biomarker detection sensors. Research. 2020. https://doi.org/10.34133/2020/7949037. 2020:2020/7949037.10.34133/2020/7949037 ↗
58. Verma A, Stellacci F. Effect of surface properties on Nanoparticle-Cell interactions. Small. 2010;6:12–21. https://doi.org/10.1002/smll.200901158.10.1002/smll.200901158 ↗
59. Nakamura Y, Watanabe K, Fukuzawa Y, Ichikawa M. Observation of the quantum-confinement effect in individual ge nanocrystals on oxidized Si substrates using scanning tunneling spectroscopy. Appl Phys Lett. 2005;87:133119. https://doi.org/10.1063/1.2067711.10.1063/1.2067711 ↗
60. Borgohain K, Singh JB, Rao MVR, Shripathi T, Mahamuni S. Quantum size effects in CuO nanoparticles. Phys Rev B. 2000;61:11093–6. https://doi.org/10.1103/PhysRevB.61.11093.10.1103/PhysRevB.61.11093 ↗
61. Pan H, Feng YP. Semiconductor nanowires and nanotubes: effects of size and Surface-to-Volume ratio. ACS Nano. 2008;2:2410–4. https://doi.org/10.1021/nn8004872.10.1021/nn8004872 ↗
62. Govorov AO, Fan Z, Hernandez P, Slocik JM, Naik RR. Theory of circular dichroism of nanomaterials comprising chiral molecules and nanocrystals: plasmon Enhancement, dipole Interactions, and dielectric effects. Nano Lett. 2010;10:1374–82. https://doi.org/10.1021/nl100010v.10.1021/nl100010v ↗
63. Singh A, Sharma A, Ahmed A, et al. Recent advances in electrochemical biosensors: applications, challenges, and future scope. Biosensors. 2021;11:336. https://doi.org/10.3390/bios11090336.10.3390/bios11090336 ↗
64. Jo H, Gu H, Jeon W, et al. Electrochemical aptasensor of cardiac troponin I for the early diagnosis of acute myocardial infarction. Anal Chem. 2015;87:9869–75. https://doi.org/10.1021/acs.analchem.5b02312.10.1021/acs.analchem.5b02312 ↗
65. Asl SK, Rahimzadegan M. Recent advances in the fabrication of Nano-aptasensors for the detection of troponin as a main biomarker of acute myocardial infarction. Crit Rev Anal Chem N D. https://doi.org/10.1080/10408347.2021.196772110.1080/10408347.2021.1967721 ↗
66. Sun D, Luo Z, Lu J, et al. Electrochemical dual-aptamer-based biosensor for nonenzymatic detection of cardiac troponin I by nanohybrid electrocatalysts labeling combined with DNA nanotetrahedron structure. Biosens Bioelectron. 2019;134:49–56. https://doi.org/10.1016/j.bios.2019.03.049.10.1016/j.bios.2019.03.049 ↗
67. Reddy KK, Bandal H, Satyanarayana M, et al. Recent trends in electrochemical sensors for vital biomedical markers using hybrid nanostructured materials. Adv Sci. 2020;7:1902980. https://doi.org/10.1002/advs.201902980.10.1002/advs.201902980 ↗
68. Surya SG, Majhi SM, Agarwal DK, et al. A label-free aptasensor FET based on Au nanoparticle decorated Co 3 O 4 nanorods and a SWCNT layer for detection of cardiac troponin T protein. J Mater Chem B. 2020;8:18–26. https://doi.org/10.1039/C9TB01989H.10.1039/C9TB01989H ↗
69. Karaman O, Özcan N, Karaman C, Yola BB, Atar N, Yola ML. Electrochemical cardiac troponin I immunosensor based on nitrogen and boron-doped graphene quantum Dots electrode platform and Ce-doped SnO2/SnS2 signal amplification. Mater Today Chem. 2022;23:100666. https://doi.org/10.1016/j.mtchem.2021.100666.10.1016/j.mtchem.2021.100666 ↗
70. Wang B, Wang C, Li Y, Liu X, Wu D, Wei Q. Electrochemiluminescence biosensor for cardiac troponin I with signal amplification based on a MoS 2 @Cu 2 O–Ag-modified electrode and Ce:ZnO-NGQDs. Analyst. 2022;147:4768–76. https://doi.org/10.1039/D2AN01341J.10.1039/D2AN01341J ↗
71. Shi L, Sun Y, Mi L, Li T. Target-catalyzed self-growing spherical nucleic acid enzyme (SNAzyme) as a double amplifier for ultrasensitive chemiluminescence MicroRNA detection. ACS Sens. 2019;4:3219–26. https://doi.org/10.1021/acssensors.9b01655.10.1021/acssensors.9b01655 ↗
72. Tiambeng TN, Roberts DS, Brown KA, et al. Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum. Nat Commun. 2020;11:3903. https://doi.org/10.1038/s41467-020-17643-1.10.1038/s41467-020-17643-1 ↗
73. Qian Y, Feng J, Fan D, et al. A sandwich-type photoelectrochemical immunosensor for NT-pro BNP detection based on F-Bi2WO6/Ag2S and GO/PDA for signal amplification. Biosens Bioelectron. 2019;131:299–306. https://doi.org/10.1016/j.bios.2019.02.029.10.1016/j.bios.2019.02.029 ↗
74. Li X, Lu P, Wu B, et al. Electrochemiluminescence quenching of luminol by CuS in situ grown on reduced graphene oxide for detection of N-terminal pro-brain natriuretic peptide. Biosens Bioelectron. 2018;112:40–7. https://doi.org/10.1016/j.bios.2018.04.030.10.1016/j.bios.2018.04.030 ↗
75. Hsieh Y-F, Lin K-J. Rapid-test kit for cardiac troponin I: a reliable enzyme-linked-immuno-substrate-assay-based biosensor for daily-use naked-eye detection and Pharmacokinetic studies for myocardial infarction in cardiovascular disease. ACS Pharmacol Transl Sci. 2024;7:2369–78. https://doi.org/10.1021/acsptsci.4c00218.10.1021/acsptsci.4c00218 ↗
76. Huang Y, Zhang Y, Lv J, Shao Y, Yang D, Cong Y. Direct fabrication of NbS2 nanoflakes on carbon fibers by atomic layer deposition for ultrasensitive cardiac troponin I detection. Nanoscale Adv. 2023;5:830–9. https://doi.org/10.1039/d2na00827k.10.1039/d2na00827k ↗
77. Lee I, Luo X, Huang J, Cui XT, Yun M. Detection of cardiac biomarkers using single polyaniline nanowire-based conductometric biosensors. Biosensors. 2012;2:205–20. https://doi.org/10.3390/bios2020205.10.3390/bios2020205 ↗
78. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American heart association. Circulation. 2024;149. https://doi.org/10.1161/CIR.0000000000001209.10.1161/CIR.0000000000001209 ↗
79. Ashaduzzaman M, Deshpande SR, Murugan NA, Mishra YK, Turner APF, Tiwari A. Author correction: on/off-switchable LSPR nano-immunoassay for troponin-T. Sci Rep. 2022;12:3813. https://doi.org/10.1038/s41598-022-07807-y.10.1038/s41598-022-07807-y ↗
80. Han G-R, Goncharov A, Eryilmaz M, et al. Deep learning-enhanced paper-based vertical flow assay for high-sensitivity troponin detection using nanoparticle amplification. ACS Nano. 2024;18:27933–48. https://doi.org/10.1021/acsnano.4c05153.10.1021/acsnano.4c05153 ↗
81. Yu Z, Lin Q, Gong H, Li M, Tang D. Integrated solar-powered MEMS-based photoelectrochemical immunoassay for point-of-care testing of cTnI protein. Biosens Bioelectron. 2023;223:115028. https://doi.org/10.1016/j.bios.2022.115028.10.1016/j.bios.2022.115028 ↗
82. Li P, Ye Y, Li Y, Xie Z, Ye L, Huang J. A MoS2 nanosheet-based CRISPR/Cas12a biosensor for efficient MiRNA quantification for acute myocardial infarction. Biosens Bioelectron. 2024;251:116129. https://doi.org/10.1016/j.bios.2024.116129.10.1016/j.bios.2024.116129 ↗
83. Cui F, Chen W, Wang P, et al. Gold metallene-based ECL biosensor to detect miRNA-126 for coronary artery calcification diagnosis. Biosens Bioelectron. 2025;271:116993. https://doi.org/10.1016/j.bios.2024.116993.10.1016/j.bios.2024.116993 ↗
84. Tripathy S, Wai NK, Sharma S, et al. A locked aptamer-magnetic nanoparticle assay for cardiac troponin I classification to support myocardial infarction diagnosis in resource-limited environments. Biosens Bioelectron. 2025;286:117590. https://doi.org/10.1016/j.bios.2025.117590.10.1016/j.bios.2025.117590 ↗
85. Peng X, Xu R, Yu F, Xu J, Wang Y, Wang S. A magnetic dual-aptamer electrochemical sensor with MOF-on-MOF-derived electrocatalyst as a signal amplifier for sensitive detection of cardiac troponin I. Talanta. 2025;283:127177. https://doi.org/10.1016/j.talanta.2024.127177.10.1016/j.talanta.2024.127177 ↗
86. Poosinuntakul N, Chanmee T, Porntadavity S, Chailapakul O, Apilux A. Silver-enhanced colloidal gold dip strip immunoassay integrated with smartphone-based colorimetry for sensitive detection of cardiac marker troponin I. Sci Rep. 2022;12:19866. https://doi.org/10.1038/s41598-022-24458-1.10.1038/s41598-022-24458-1 ↗
87. Zheng P, Wu L, Raj P, et al. Multiplexed SERS detection of serum cardiac markers using plasmonic metasurfaces. Adv Sci. 2024;11:2405910. https://doi.org/10.1002/advs.202405910.10.1002/advs.202405910 ↗
88. Zhong Y, Zeng X, Zeng Y, et al. Nanomaterials-based imaging diagnosis and therapy of cardiovascular diseases. Nano Today. 2022;45:101554. https://doi.org/10.1016/j.nantod.2022.101554.10.1016/j.nantod.2022.101554 ↗
89. Ouyang J, Xie A, Zhou J, et al. Minimally invasive nanomedicine: nanotechnology in photo-/ultrasound-/radiation-/magnetism-mediated therapy and imaging. Chem Soc Rev. 2022;51:4996–5041. https://doi.org/10.1039/d1cs01148k.10.1039/d1cs01148k ↗
90. MacRitchie N, Noonan J, Guzik TJ, Maffia P. Molecular imaging of cardiovascular inflammation. Br J Pharmacol. 2021;178:4216–45. https://doi.org/10.1111/bph.15654.10.1111/bph.15654 ↗
91. Daubert MA, Tailor T, James O, Shaw LJ, Douglas PS, Koweek L. Multimodality cardiac imaging in the 21st century: evolution, advances and future opportunities for innovation. Br J Radiol. 2021;94:20200780. https://doi.org/10.1259/bjr.20200780.10.1259/bjr.20200780 ↗
92. Jeon M, Halbert M, Stephen ZR, Zhang M. Iron oxide nanoparticles as T-1 contrast agents for magnetic resonance imaging: fundamentals, challenges, applications, and prospectives. Adv Mater. 2021;33:1906539. https://doi.org/10.1002/adma.201906539.10.1002/adma.201906539 ↗
93. Kubota A, Frangogiannis NG. Macrophages in myocardial infarction. Am J Physiology-Cell Physiol. 2022;323:C1304–24. https://doi.org/10.1152/ajpcell.00230.2022.10.1152/ajpcell.00230.2022 ↗
94. Lu Y, Huang J, Neverova N, Nguyen K-L. USPIOs as targeted contrast agents in cardiovascular magnetic resonance imaging. CURR CARDIOVASC IMAGING REP. 2021;14:2. https://doi.org/10.1007/s12410-021-09552-8.10.1007/s12410-021-09552-8 ↗
95. Moonen RPM, Coolen BE, Sluimer JC, Daemen MJAP, Strijkers GJ. Iron oxide nanoparticle uptake in mouse brachiocephalic artery atherosclerotic plaque quantified by T-2-Mapping MRI. Pharmaceutics. 2021;13:279. https://doi.org/10.3390/pharmaceutics13020279.10.3390/pharmaceutics13020279 ↗
96. Clough TJ, Jiang L, Wong K-L, Long NJ. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents. Nat Commun. 2019;10:1420. https://doi.org/10.1038/s41467-019-09342-3.10.1038/s41467-019-09342-3 ↗
97. Cheng T-M, Li R, Kao Y-CJ, et al. Synthesis and characterization of Gd-DTPA/fucoidan/peptide complex nanoparticle and in vitro magnetic resonance imaging of inflamed endothelial cells. Mater Sci Eng C-Mater Biol Appl. 2020;114:111064. https://doi.org/10.1016/j.msec.2020.111064.10.1016/j.msec.2020.111064 ↗
98. Tarighatnia A, Fouladi MR, Nader ND, Aghanejad A, Ghadiri H. Recent trends of contrast agents in ultrasound imaging: a review of the classifications and applications. Mater Adv. 2022;3:3726–41. https://doi.org/10.1039/d1ma00969a.10.1039/d1ma00969a ↗
99. Wang C, Yang S, Chen X, He Q, Zhao K, Hu J. Molecular imaging diagnosis of atherosclerotic vulnerable plaque in rabbit carotid artery using a self-assembled nanoscale ultrasound microbubble contrast agent. Rev Cardiovasc Med. 2021;22:1657–66. https://doi.org/10.31083/j.rcm2204173.10.31083/j.rcm2204173 ↗
100. Kiaie N, Gorabi AM, Penson PE, et al. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. Drug Discov Today. 2020;25:58–72. https://doi.org/10.1016/j.drudis.2019.09.005.10.1016/j.drudis.2019.09.005 ↗